CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Performing paravertebral nerve block with lipo-bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06231355
NCT06231355Phase 4Completed

Efficacy of Liposomal Bupivacaine Versus Conventional Bupivacaine for Pain Control in Patients Undergoing Laparoscopic Radical Nephrectomy: A Pilot Randomized Trial

Peking University First Hospital·interventional·Posted Jan 30, 2024·Updated Jul 30, 2025

In Brief

A Phase 4 clinical trial evaluating Performing paravertebral nerve block with lipo-bupivacaine and Performing paravertebral nerve block with bupivacaine for Local Anesthetics and 3 related conditions. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The goal of this pilot study is to test the hypothesis that liposomal bupivacaine extends the duration of paravertebral block in patients undergoing radical nephrectomy, achieving improved analgesia compared to conventional bupivacaine. The main questions it aims to answer are: * Area under curve of numeric rating scale of pain from 12 to 72 h after surgery. * Cumulative opioid consumption during the period of 12 to 72 h after surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedJan 30, 2024
Enrollment StartFeb 21, 2024
Primary CompletionSep 9, 2024
Study CompletionOct 14, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.4 years ago

Interventions

Performing paravertebral nerve block with lipo-bupivacainedrug

Paravertebral block is performed using liposomal bupivacaine.

Performing paravertebral nerve block with bupivacainedrug

Paravertebral block is performed using bupivacaine.